Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
The neuroprotective mechanism of 1‐(R)‐aminoindan, the major metabolite of the anti‐parkinsonian drug rasagiline
View through CrossRef
J. Neurochem.(2010)112, 1131–1137.AbstractThe anti‐parkinsonian drug, rasagiline [N‐propargyl‐1‐(R)‐aminoindan; Azilect®], is a secondary cyclic benzylamine and indane derivative, which provides irreversible, potent monoamine oxidase‐B (MAO‐B) inhibition and possesses neuroprotective and neurorestorative activities. A prospective clinical trial has shown that rasagiline confers significant symptomatic improvement and demonstrated alterations in Parkinson’s disease progression. Rasagiline is primarily metabolized by hepatic cytochrome P‐450 to form its major metabolite, 1‐(R)‐aminoindan, a non‐amphetamine, weak reversible MAO‐B inhibitor compound. Recent studies indicated the potential neuroprotective effect of 1‐(R)‐aminoindan, suggesting that it may contribute to the overall neuroprotective and antiapoptotic effects of its parent compound, rasagiline. This review article briefly highlights the molecular mechanisms underlying the neuroprotective properties of the active metabolite of rasagiline, 1‐(R)‐aminoindan, supporting the valuable potential of rasagiline for disease modification.
Title: The neuroprotective mechanism of 1‐(R)‐aminoindan, the major metabolite of the anti‐parkinsonian drug rasagiline
Description:
J.
Neurochem.
(2010)112, 1131–1137.
AbstractThe anti‐parkinsonian drug, rasagiline [N‐propargyl‐1‐(R)‐aminoindan; Azilect®], is a secondary cyclic benzylamine and indane derivative, which provides irreversible, potent monoamine oxidase‐B (MAO‐B) inhibition and possesses neuroprotective and neurorestorative activities.
A prospective clinical trial has shown that rasagiline confers significant symptomatic improvement and demonstrated alterations in Parkinson’s disease progression.
Rasagiline is primarily metabolized by hepatic cytochrome P‐450 to form its major metabolite, 1‐(R)‐aminoindan, a non‐amphetamine, weak reversible MAO‐B inhibitor compound.
Recent studies indicated the potential neuroprotective effect of 1‐(R)‐aminoindan, suggesting that it may contribute to the overall neuroprotective and antiapoptotic effects of its parent compound, rasagiline.
This review article briefly highlights the molecular mechanisms underlying the neuroprotective properties of the active metabolite of rasagiline, 1‐(R)‐aminoindan, supporting the valuable potential of rasagiline for disease modification.
Related Results
Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro
Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro
AbstractThe anti‐Parkinson, selective irreversible monoamine oxidase B inhibitor drug, rasagiline (Azilect), recently approved by the US Food and Drug Administration, has been show...
The importance of propargylamine moiety in the anti‐ Parkinson drug rasagiline and its derivatives for MAPK‐ dependent amyloid precursor protein processing
The importance of propargylamine moiety in the anti‐ Parkinson drug rasagiline and its derivatives for MAPK‐ dependent amyloid precursor protein processing
ABSTRACT
Rasagiline [N‐propargyl‐(1R)‐aminoindan] a highly potent selective irreversible monoamine oxidase (MAO)‐B inhibitor exerts neuroprot...
Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition
Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition
AbstractMitochondria are involved directly in cell survival and death. The assumption has been made that drugs that protect mitochondrial viability and prevent apoptotic cascade‐in...
Neuroprotection via pro‐survival protein kinase C isoforms associated with Bcl‐2 family members
Neuroprotection via pro‐survival protein kinase C isoforms associated with Bcl‐2 family members
This study provides new insights into neuroprotection involving interaction of protein kinase C (PKC) pathway with Bcl‐2 family proteins. Using a model of serum deprivation, we inv...
Striking Neurochemical and Behavioral Differences in the Mode of Action of Selegiline and Rasagiline
Striking Neurochemical and Behavioral Differences in the Mode of Action of Selegiline and Rasagiline
Selegiline and rasagiline are two selective monoamine oxidase B (MAO-B) inhibitors used in the treatment of Parkinson’s disease. In their clinical application, however, differences...
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
BACKGROUND
As of July 2020, a Web of Science search of “machine learning (ML)” nested within the search of “pharmacokinetics or pharmacodynamics” yielded over 100...
A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo‐APP translation and processing
A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo‐APP translation and processing
The recent therapeutic approach in which drug candidates are designed to possess diverse pharmacological properties and act on multiple targets has stimulated the development of th...
Regulation of Bcl‐2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine
Regulation of Bcl‐2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine
ABSTRACT
The anti‐Parkinson drug, rasagiline (N‐propargyl‐(1R)‐aminoindan) promotes neuronal survival, via neuroprotective activity related to its propargyl moiet...